Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US90466Y1038
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG01163JG34
UNCY
Unicycive Therapeutics, Inc.
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Unicycive Therapeutics, Inc.
ISIN
US90466Y1038
TICKER
UNCY
MIC
XNAS
REUTERS
UNCY.OQ
BLOOMBERG
UNCY US
Fr., 18.09.2026       Unicycive Therapeutics
US90466Y1038

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercia...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 18.09.2026       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 18, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline....
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 18.09.2026       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 17, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 20...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 17.09.2026       Unicycive Therapeutics
US90466Y1038

A securities class action alleges Unicycive Therapeutics spent six months telling shareholders its OLC application was on track while never verifying, through its own inspection, that the manufacturer at the center of the FDA's prior rejection had fixed anything.NEW YORK, Sept. 17, 2026 /PRNewswire/ -- SueWallSt notifies investors in Unicycive The...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 16.09.2026       Unicycive Therapeutics
US90466Y1038

A securities class action alleges Unicycive Therapeutics told shareholders its oxylanthanum carbonate application was on track without ever inspecting its third-party manufacturer's facility for cGMP compliance. UNCY purchasers who lost $3.01 per share have specific rights under the federal securities laws.NEW YORK, Sept. 16, 2026 /PRNewswire/ --...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 16.09.2026       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 15, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If y...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 15.09.2026       Unicycive Therapeutics
US90466Y1038

San Diego, California--(Newsfile Corp. - September 15, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 15.09.2026       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 14.09.2026       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 14, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If y...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
So., 13.09.2026       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Unicycive Therapeutics
US90466Y1038

LOS ANGELES, Sept. 11, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Unicycive Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR UNICYCIVE THERAPEUTICS, INC. I...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 11, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 20...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers.This lawsuit seeks to recover damages against Defendants for allege...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Unicycive Therapeutics
US90466Y1038

Levi & Korsinsky, LLP notifies institutional investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@lev...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partne...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 11.09.2026       Unicycive Therapeutics
US90466Y1038

If you have suffered a loss on your Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.Investors have...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 10, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers.This lawsuit seeks to recover damages against Defendants for allege...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Unicycive Therapeutics
US90466Y1038

A securities class action contends Unicycive Therapeutics promised shareholders an FDA decision on June 29, 2026 and a commercial launch of oxylanthanum carbonate "later this year," while allegedly never inspecting the third-party manufacturing facility that had already triggered one Complete Response Letter.NEW YORK, Sept. 10, 2026 /PRNewswire/ -...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 9, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 202...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 09.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"). A class action lawsuit h...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Unicycive Therapeutics
US90466Y1038

LOS ANGELES, Sept. 9, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Unicycive Therapeutics, Inc. (UNCY) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UNICYCIVE...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 9, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Unicycive Therapeutics
US90466Y1038

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026 incl...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Unicycive Therapeutics
US90466Y1038

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) common stock between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”). Unicycive Therapeutics, Inc. investo...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Unicycive Therapeutics
US90466Y1038

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“” or the “Company”) (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. This p...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 09.09.2026       Unicycive Therapeutics
US90466Y1038

A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verifie...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Unicycive Therapeutics
US90466Y1038

Law Offices of Howard G. Smith reminds investors of the upcoming November 2, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”). IF YOU...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Unicycive Therapeutics
US90466Y1038

SAN DIEGO, Sept. 8, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology compan...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed....
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Unicycive Therapeutics
US90466Y1038

Rosen Law Firm, a global investor rights law firm, announces a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026. Unicycive describes itself as a “a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Unicycive Therapeutics
US90466Y1038

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers. This lawsuit seeks t...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 8, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Unicycive Therapeutics
US90466Y1038

SAN DIEGO, Sept. 8, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology compan...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 07.09.2026       Unicycive Therapeutics
US90466Y1038

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 2, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026, inc...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 07.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 7, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 07.09.2026       Unicycive Therapeutics
US90466Y1038

The DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of UNCY dur...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 06.09.2026       Unicycive Therapeutics
US90466Y1038

New York, New York--(Newsfile Corp. - September 6, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 05.09.2026       Unicycive Therapeutics
US90466Y1038

Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securiti...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 05.09.2026       Unicycive Therapeutics
US90466Y1038

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Unicycive Therapeutics (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities during the period of December 29, 2025 through June 29, 2026, inclusive (“the Class Period”). Investors are encouraged to contact Lauren Molinaro...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 04.09.2026       Unicycive Therapeutics
US90466Y1038

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) common stock between December 29, 2025 and June 29, 2026, inclusive (the “Class Period”). Unicycive Therapeutics, Inc. investors have until November 2, 2...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 04.09.2026       Unicycive Therapeutics
US90466Y1038

Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commerci...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 04.09.2026       Unicycive Therapeutics
US90466Y1038

Glancy Prongay Wolke & Rotter LLP (“GPWR”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Patel v. Unicycive Therapeutics, Inc. et al., Case No. 25-cv-09559, on behalf of persons and entities that purchased or otherwise acquired Unicycive Therapeutics,...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 01.09.2026       Unicycive Therapeutics
US90466Y1038

LOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global In...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 12.08.2026       Unicycive Therapeutics
US90466Y1038

- Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.07.2026       Unicycive Therapeutics
US90466Y1038

The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATIO...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 08.07.2026       Unicycive Therapeutics
US90466Y1038

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MO...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 08.07.2026       Unicycive Therapeutics
US90466Y1038

Law Offices of Howard G. Smith announces an investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UNICYCIVE THERAPEUTICS, INC. (UNCY), CONTACT THE LAW OFFICES OF HOWARD G. SM...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 08.07.2026       Unicycive Therapeutics
US90466Y1038

The Law Offices of Frank R. Cruz announces an investigation of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON UNICYCIVE THERAPEUTICS, INC. (UNCY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 06.07.2026       Unicycive Therapeutics
US90466Y1038

Boston, Massachusetts--(Newsfile Corp. - July 6, 2026) - Block & Leviton is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) for potential securities law violations. Investors who have lost money in their Unicycive Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more de...
Zur Nachricht
Unicycive Therapeutics
Charts & Research Termsheets Terminal
Permalink